XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenues:        
Total revenue $ 179.3 $ 189.4 $ 344.2 $ 362.5
Costs and expenses:        
Research and development expense 20.3 19.5 41.5 42.6
Selling, general, and administrative expense 127.1 135.2 237.7 281.6
Goodwill and long-lived asset impairment charges 0.0 1.8 10.7 1.8
Total costs and expenses 197.1 210.2 387.6 430.0
Operating loss (17.8) (20.8) (43.4) (67.5)
Other income (expense):        
Interest income 0.4 0.2 0.5 0.4
Interest expense (0.6) (2.0) (1.5) (5.0)
Other 0.1 18.8 0.1 18.7
Total other income (expense), net (0.1) 17.0 (0.9) 14.1
Loss before income tax (17.9) (3.8) (44.3) (53.4)
Income tax expense (benefit) (3.8) 0.9 (9.7) (9.2)
Net loss (14.1) (4.7) (34.6) (44.2)
Net loss attributable to non-controlling interest 0.0 0.0 0.0 0.0
Net loss attributable to Myriad Genetics, Inc. stockholders $ (14.1) $ (4.7) $ (34.6) $ (44.2)
Net loss per share:        
Basic (dollars per share) $ (0.18) $ (0.06) $ (0.43) $ (0.58)
Diluted (dollars per share) $ (0.18) $ (0.06) $ (0.43) $ (0.58)
Weighted average shares outstanding:        
Basic (shares) 80.4 77.2 80.3 76.6
Diluted (shares) 80.4 77.2 80.3 76.6
Molecular diagnostic testing        
Revenues:        
Total revenue $ 179.3 $ 178.7 $ 344.2 $ 338.3
Costs and expenses:        
Cost of revenue 49.7 48.0 97.7 92.1
Pharmaceutical and clinical services        
Revenues:        
Total revenue 0.0 10.7 0.0 24.2
Costs and expenses:        
Cost of revenue $ 0.0 $ 5.7 $ 0.0 $ 11.9